The estimated Net Worth of Enterprise Associates 13 Lp... is at least $608 Tausend dollars as of 25 October 2022. Enterprise Lp owns over 1,784,109 units of PhaseBio Pharmaceuticals stock worth over $340,513 and over the last 2 years Enterprise sold PHAS stock worth over $267,616.
Sign up
Enterprise Lp PHAS stock SEC Form 4 insiders trading
Enterprise has made over 1 trades of the PhaseBio Pharmaceuticals stock since 2022, according to the Form 4 filled with the SEC. Most recently Enterprise sold 1,784,109 units of PHAS stock worth $267,616 on 25 October 2022.
The largest trade Enterprise's ever made was selling 1,784,109 units of PhaseBio Pharmaceuticals stock on 25 October 2022 worth over $267,616. On average, Enterprise trades about 1,784,109 units every 0 days since 2022. As of 25 October 2022 Enterprise still owns at least 4,857,525 units of PhaseBio Pharmaceuticals stock.
You can see the complete history of Enterprise Lp stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at PhaseBio Pharmaceuticals
Over the last 6 years, insiders at PhaseBio Pharmaceuticals have traded over $361,083 worth of PhaseBio Pharmaceuticals stock and bought 24,000 units worth $81,960 . The most active insiders traders include Clay Thorp, Enterprise Associates 13 Lp... und Nancy J Hutson. On average, PhaseBio Pharmaceuticals executives and independent directors trade stock every 52 days with the average trade being worth of $5,138. The most recent stock trade was executed by Clay Thorp on 19 May 2023, trading 3,750 units of PHAS stock currently worth $263.
What does PhaseBio Pharmaceuticals do?
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.
What does PhaseBio Pharmaceuticals's logo look like?
Complete history of Enterprise Lp stock trades at PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals executives and stock owners
PhaseBio Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Jonathan Mow,
Chief Executive Officer, Director -
Jonathan P. Mow,
Pres, CEO & Director -
John Lee,
Chief Medical Officer -
John Sharp,
Chief Financial Officer -
Dr. John S. Lee,
Chief Medical Officer -
John P. Sharp,
Chief Financial Officer -
Clay Thorp,
Co-Founder, Independent Chairman of the Board -
Peter Klein,
Independent Director -
Nancy Hutson,
Independent Director -
Richard van den Broek,
Independent Director -
Caroline Loewy,
Independent Director -
Edmund Harrigan,
Independent Director -
Alex Sapir,
Independent Director -
Michael York,
Vice President - Corporate Development and Commercial Strategy -
Jim Ballance,
Vice President - Research and Scientific Affairs -
Susan Arnold,
Vice President - Preclinical and Chemistry, Manufacturing and Controls -
Kristophe Hanson,
Vice President - Head of Legal, Corporate Secretary -
Glen Burkhardt,
Vice President - Human Resources -
Jonathan J. Birchall,
Chief Commercial Officer -
Glen Burkhardt,
VP of HR -
Lauren Richardson,
Global Head of Regulatory Affairs & Quality Assurance -
Kristopher L. Hanson,
VP, Head of Legal & Corp. Sec. -
Bibhash Mukhopadhyay,
Director -
David James Ballance,
VP, Research and Sci. Affairs -
Linda Tufts,
Director -
William D. Humphries,
Director -
Jonathan Birchall,
Chief Commercial Officer -
Enterprise Associates 13 Lp...,